Kenya Infectious Disease Therapeutics Market Analysis

Kenya Infectious Disease Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Kenya infectious disease therapeutics market will reach a value of $128.3 Mn from $83.9 Mn in 2022, growing at a CAGR of 5.5% during 2022-30. The Infectious Disease Therapeutics in Kenya is dominated by a few domestic pharmaceutical companies such as Kenya Medical Research Institute, Bio-Ken, and Kenya Vaccines and Immunizations Institute. The Infectious Disease Therapeutics market in Kenya is segmented into different therapeutic areas and different disease types. The major factors affecting the Kenya infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious disease treatment in various areas of Kenya.

ID: IN10KEPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Vishwa Modhia

Buy Now

Kenya Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Kenya infectious disease therapeutics market will reach a value of $128.3 Mn from $83.9 Mn in 2022, growing at a CAGR of 5.5% during 2022-30.

Kenya is a lower middle-income, developing country in Eastern Africa bordering the Indian Ocean and Lake Victoria. According to the World Factbook, Kenya is extremely vulnerable to the infectious diseases listed below. Food or waterborne infections include bacterial and protozoal diarrhea, hepatitis A, and typhoid fever. In Kenya, infectious diseases caused by water contact, such as schistosomiasis, are common. Rabies, malaria, dengue fever, and Rift Valley fever are among the major infectious diseases in Kenya.

Kenya has a rising pharmaceutical sector in terms of medicine use. According to Kenya Pharmaceutical Association research, the Kenyan pharmaceutical market is expected to be worth $830 Mn in 2020, with medications for infectious diseases being one of the most important therapeutic categories. Kenya's government spends 4.6% of its GDP on healthcare.

Kenya Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Kenya has been fighting malaria by improving access to diagnostic tools and producing new treatments. Kenya is continuing to implement the president's Big Four Agenda, which focuses on food security, manufacturing employment, universal and inexpensive health care, and affordable housing. Kenya has a rapidly rising population and a developing middle class. These aspects could boost Kenya's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and treatments necessitates adherence to regulatory rules established by organisations such as Kenya's Pharmacy and Poisons Board (PPB). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Kenya suffers recurrent constraints due to a lack of infrastructure and a paucity of skilled workers. These factors may deter new entrants into the Kenya infectious disease therapeutics market.

Competitive Landscape

Key Players

  • Kenya Medical Research Institute (KEMRI) - KEMRI is a research institution in Kenya that conducts research on a wide range of health issues, including infectious diseases. KEMRI has played a major role in the development of diagnostic tools and treatment for infectious diseases such as malaria, tuberculosis, and HIV/AIDS
  • Bio-Ken Limited - Bio-Ken Limited is a Kenyan biotechnology company that specializes in the development of vaccines and diagnostic tools for infectious diseases such as malaria, HIV/AIDS, and tuberculosis
  • Kenya Vaccines and Immunizations Institute (KAVI) - KAVI is a research institution in Kenya that is involved in the development of vaccines for infectious diseases such as HIV/AIDS and tuberculosis
  • Medisel Kenya
  • Universal Corporation

Recent Notable Updates

July 2022: Tonix Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced a partnership with the Kenya Medical Research Institute (KEMRI) to organise, obtain regulatory clearance for, and potentially perform a Phase 1 clinical study in Kenya to develop TNX-8011 as a monkeypox vaccine. Tonix and KEMRI will collaborate to get regulatory approval in Kenya in order to begin Phase 1 clinical research of TNX-801. The research is set to begin in the first half of 2023.

Healthcare Policies and Reimbursement Scenarios

The Pharmacy and Poisons Board oversees the regulation of infectious disease medicines in Kenya (PPB). The National Hospital Insurance Fund (NHIF) is in charge of overseeing the national health insurance programme, which covers a variety of healthcare services, including pharmaceuticals and infectious disease treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

  • Vaccines
  • Drugs

By Applications (Revenue, USD Billion):

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • Tuberculosis
  • Others

By Disease Type (Revenue, USD Billion):

  • Viral Diseases
  • Bacterial Diseases
  • Fungal Diseases
  • Parasitic Diseases
  • Others

By Target Organism (Revenue, USD Billion):

  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-Parasitic
  • Others

By End User (Revenue, USD Billion):

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

By 2030, it is anticipated that the Kenya infectious disease therapeutics market will reach a value of $128.3 Mn from $83.9 Mn in 2022, growing at a CAGR of 5.5% during 2022-2030.

In Kenya, the regulation of infectious disease therapeutics is overseen by the Pharmacy and Poisons Board (PPB).

The Infectious Disease Therapeutics in Kenya is dominated by a few domestic pharmaceutical companies such as Kenya Medical Research Institute, Bio-Ken and Kenya Vaccines and Immunizations Institute.


Last updated on: 14 December 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up